Clinical trials have shown that ICIs, especially those targeting the PD-1/PD-L1 pathway, can significantly enhance antitumor immunity in breast cancer, particularly when used in combination with chemotherapy [138]. This evidence concerns the gene CD274 and breast carcinoma.